Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.

Between an increased cultural focus on health and wellness and everyone (and everyone’s mother) using smartphones and other wearable tech, weight loss apps aren’t going anywhere. Like many ...

“Unhealthy weight loss can lead to a state called sarcopenia, which is when you’ve lost so much muscle mass that you don’t have enough for healthy function,” says Naomi Parrella, M.D., chief of ...

The Alaska Watchman aims to raise awareness of key issues affecting Alaskans. Coming from a broadly Judeo-Christian perspective, we are committed to the highest standards of journalism and ethical ...

On the fourth-quarterearnings call management shared that HIMS continues to primarily focus on its weight loss category to bring care to individuals who stand to benefit from its oral-based ...